Inhibikase Therapeutics (IKT) Operating Margin Growth (1y) (2021 - 2023)

Inhibikase Therapeutics (IKT) Operating Margin Growth (1y) (2021 - 2023) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Operating Margin Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -143.00
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 78.00
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 1,049.00
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 1,238.00
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -10,520.00
7 Royalty Pharma 33.72 Bn 35.84 Bn - -1,651.00
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 2,002.00
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 29,091.00
10 Inhibikase Therapeutics 420.72 Mn 261.70 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2023 -44.03 Bn
Sep 30, 2023 5.59 Mn
Jun 30, 2023 6.55 Mn
Mar 31, 2023 277,384.00
Dec 31, 2022 25.25 Mn
Sep 30, 2022 -6.05 Mn
Jun 30, 2022 -7.06 Mn
Mar 31, 2022 -989,489.00
Dec 31, 2021 -25.86 Mn
Sep 30, 2021 40,022.00
Jun 30, 2021 -433.00
Mar 31, 2021 1,286.00